Navigation Links
NeuroPhage to Participate in World's First G8 Dementia Summit
Date:12/3/2013

CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders, innovators, technology pioneers, breakthrough researchers and investors. The Summit will explore the coordination of efforts to shape an effective international solution to dementia, a condition that affects over 35 million people worldwide, including looking for effective therapies to slow dementia's impact. The G8 Dementia Summit will take place in London, UK, on December 11, 2013.

"We applaud this groundbreaking initiative that the Prime Minister and the Health Secretary have undertaken to bring together leaders from government, research and finance to focus on addressing the enormous health and economic burden that dementia has on patients and families around the world," said Jonathan Solomon, President and Chief Executive Officer of NeuroPhage. "Dementia has proved to be a challenging indication to treat, as the biology behind the various conditions is complex. We are honored to take part in this ambitious international effort in hopes to create a greater collaborative approach worldwide to better achieve our common goals of treating and preventing dementia."

About NeuroPhage  

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. In addition to targeting multiple misfolded pathological proteins, this unique disease-modifying approach recognizes early amyloid assemblies and existing protein aggregates to maximize potential therapeutic effect. NeuroPhage is initially developing candidates to treat Alzheimer's and Parkinson's disease, where a number of different misfolded proteins are present and their interactions can exacerbate disease progression.


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
2. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
3. Hill-Rom to Participate in the 25th Annual Piper Jaffray Healthcare Conference
4. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
5. Boston Scientific To Participate In 2013 Credit Suisse Healthcare Conference
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
8. montmed to participate in Vascular 2013
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Amgen To Participate At Citis 8th Annual Biotech Conference
11. China Biologic to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 ... Market Outlook to 2022", provides key market data on ... value, in millions of US dollars, volume (in units) ... Energy X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). ... data for each of these market segements, and global ...
(Date:1/16/2017)... , Jan. 16, 2017 Infusion ... devices used for administering medications in a controlled, ... used for therapeutic purposes in critical care, pain ... required to make patient,s feel comfortable and pain ... errors which would lead to serious life threatening ...
(Date:1/16/2017)... BOTHELL, Wash. , Jan. 16, 2017  Verathon ® ... devices, announced the launch of new GlideScope ® Spectrum TM ... all-new Dynamic Light Control TM and Ambient Light Reduction TM ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the following ... This year’s influenza shot seems to be having no effect on keeping this ... least half of the people around are coughing, sneezing, or sniffling , ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... in the Aesthetic Surgery Journal , the official journal of The American ... on lower eyelid retraction surgery. The procedure is designed to correct drooping, retracted ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar Medical, ... of the medical device company, effective immediately. , “This is perfect timing for ... a strong track record in medical device market development and revenue growth, particularly ...
(Date:1/15/2017)... ... 15, 2017 , ... In this role, Courtney will be responsible for developing ... & allergy friendly mark. This certification program was created by ASL and the nonprofit ... be more suitable for the 60+ million people living in the U.S. with asthma ...
Breaking Medicine News(10 mins):